Navigation Links
Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Date:9/19/2007

Novel Antibiotic Candidate Rapidly Bactericidal Against Both Cultures and

Spores of the Anaerobic Bacterium Using Multiple in Vitro Methods

CHICAGO, Sept. 19 /PRNewswire/ -- Targanta Therapeutics Corporation today released data from two studies comparing the in vitro activity of its lead antibiotic drug candidate, oritavancin, to that of other antibiotics against Clostridium difficile bacteria. Results are being presented today at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Chicago, IL.

C. difficile are anaerobic, gram-positive, spore-forming bacteria that are a major cause of morbidity in the hospitalized elderly. C. difficile infection is associated with many diseases, the most significant of which are uncomplicated diarrhea and pseudomembranous colitis, or severe infection of the colon. Often, after normal gut flora are eradicated by the use of antibiotics, it is postulated that C. difficile spores refractory to current antimicrobial therapies persist, causing recurrent infections. The U.S. Centers for Disease Control and Prevention (CDC) reports that each year nearly 10 percent of all hospitalized patients, or two million patients, contract C. difficile infections during their stay.

In the first study, presented as a poster entitled "In Vitro Susceptibility of Genotypically Distinct Clostridium difficile Strains to Oritavancin," researchers tested the activity of oritavancin versus the standards of care, metronidazole and vancomycin, against 33 genotypically distinct strains of C. difficile bacteria. Overall, in this study, oritavancin was more active than either metronidazole or vancomycin, and oritavancin was more active than vancomycin against 94% of the C. difficile strains tested by the broth macrodilution method.

In the second study, accepted as a late-breaker poster presentation entitled "Activity of Metronidazole, Vancomycin and Oritavancin Against Epidemic C
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)... 2015  iMD Companies, Inc. (ICBU) has repositioned itself as a ... grab a foothold in the hydroponic, hemp and medical marijuana ... presence in the sector, and recently partnering with the Chippewa ... and medical marijuana, iMD is committing to bring its vision ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2HyGreen Partners with RCA Medical in Johannesburg, South Africa 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... is pleased to announce that its InsightCS® Revenue Cycle ... Behavioral HealthCare (UBHC) with more than 800 users at ... UBHC, a division of the University of Medicine ... InsightCS® system,s complete, end-to-end Patient Access (Registration, Scheduling, ADT) ...
...   Curemark LLC , a Rye, New York-based drug ... III double blind randomized placebo controlled multicenter clinical trial ... endpoints.  The trial compared CM-AT to placebo in children ... demonstrate a statistically significant effect of CM-AT over placebo ...
Cached Medicine Technology:University Behavioral HealthCare Goes Live with Stockell Healthcare Systems' InsightCS® Revenue Cycle Information Management System 2Curemark LLC Reports Positive Phase III Results of CM-AT in Children With Autism 2Curemark LLC Reports Positive Phase III Results of CM-AT in Children With Autism 3
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy ... its highest annual revenues in the past three years. Today, ... wedding dresses. , According to the sales manager of the ... for them in 2015. This point can be reflected on ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... a famous dress online store for wedding dresses and other ... of wedding dresses , and launches a site-wide women’s dress ... on your big day; the wedding gown is the most ... find the most suitable wedding dress. Now, we are proud ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Hormone Therapy Recommendations Evidence of significant ... to issue recommendations against using estrogen plus progestin in ... conditions. To update its recommendations, the Task Force conducted ... determine the effectiveness of HRT in reducing risks for ...
... controlling glucose (glycemic) levels in type-2 diabetes patients may not ... a review of data from seven clinical trials, is published ... Medicine . To test the hypothesis that aggressive ... 2 diabetes mellitus, first author Steven G. Coca of Yale ...
... HealthDay Reporter , FRIDAY, May 25 (HealthDay News) -- ... doubled since 1994, researchers report, and the obesity epidemic is ... 11 Americans now develops kidney stones, according to scientists from ... contrast, only one in 20 Americans developed kidney stones back ...
... , SUNDAY, May 27 (HealthDay News) -- ... a new, small study says. Swedish researchers followed ... grade, for nine years. Some children were assigned to ... a week, plus extra training in motor-physical skills such ...
... , FRIDAY, May 25 (HealthDay News) -- Scientists say ... much better than the bland supermarket variety. The ... tomato samples representing 152 heirloom varieties, most of which ... tomatoes had an unexpectedly large chemical diversity. ...
... By Dennis Thompson HealthDay Reporter , FRIDAY, May ... kids suffering severe emotional turmoil find relief in physical pain ... achieve a form of release. But researchers now are ... these young people and help them before they do themselves ...
Cached Medicine News:Health News:Embargoed news from Annals of Internal Medicine 2Health News:As Obesity Rates Rise, Cases of Kidney Stones Double: Study 2Health News:As Obesity Rates Rise, Cases of Kidney Stones Double: Study 3Health News:More Mental Health Care Urged for Kids Who Self-Harm 2Health News:More Mental Health Care Urged for Kids Who Self-Harm 3
... with the skin to ... field. In addition to ... effect, HIBICLENS' non-drying, low ... compliance with the frequent ...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
... multi-purpose topical gel contains 10% Povidone Iodine ... action. As a pre-operative prep, Povidone Iodine ... prepping solutions under the patient, thus reducing ... is also approved as a one step ...
Medicine Products: